D.E. Shaw & Co’s Akcea Therapeutics Inc AKCA Stock Holding History

D.E. Shaw & Co’s Portfolio AKCA Stock Details AKCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-219,033	Closed	-$3.97M	–	4317
2020 Q3	$3.97M	Sell	219,033 -225,122	-51%	-$3.19M	﹤0.01%	1872
2020 Q2	$6.08M	Buy	444,155 +127,499	+40%	+$1.97M	0.01%	1520
2020 Q1	$4.53M	Buy	316,656 +149,867	+90%	+$2.46M	0.01%	1542
2019 Q4	$2.83M	Buy	166,789 +109,992	+194%	+$2.05M	﹤0.01%	2193
2019 Q3	$874K	Buy	+56,797	New	+$1.21M	﹤0.01%	2902
2019 Q2	–	Sell	-45,676	Closed	-$1.29M	–	3978
2019 Q1	$1.29M	Buy	+45,676	New	+$1.33M	﹤0.01%	2448

D.E. Shaw & Co's AKCA Position: Q4 2020 in Review

D.E. Shaw & Co sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 219,033 shares — an estimated $3.97M sold.

D.E. Shaw & Co first reported a position in AKCA in Q1 2019 and held it in 6 quarters. The position peaked at $6.08M in Q2 2020. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

D.E. Shaw & Co reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
D.E. Shaw & Co sold 219,033 Akcea Therapeutics Inc shares in Q4 2020, an estimated $3.97M.
D.E. Shaw & Co first reported a position in Akcea Therapeutics Inc in Q1 2019 and held it in 6 quarters.
D.E. Shaw & Co's Akcea Therapeutics Inc position peaked at $6.08M in Q2 2020.
0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on D.E. Shaw & Co's 13F filing for Q4 2020, filed 16 Feb 2021.